Johnson Controls announces quarterly dividend
Get Alerts JCI Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.1%
Revenue Growth %: +9.0%
Join SI Premium – FREE
MILWAUKEE, July 22, 2015 /PRNewswire/ -- The board of directors of Johnson Controls, (NYSE: JCI), a global multi-industrial company, has authorized a regular quarterly cash dividend of $0.26 per common share. The dividend is payable on October 2, 2015 to shareholders of record as of the close of business on September 4, 2015. Johnson Controls has paid consecutive dividends since 1887.
About Johnson Controls:
Johnson Controls is a global diversified technology and industrial leader serving customers in more than 150 countries. Our 170,000 employees create quality products, services and solutions to optimize energy and operational efficiencies of buildings; lead-acid automotive batteries and advanced batteries for hybrid and electric vehicles; and seating components and systems for automobiles. Our commitment to sustainability dates back to our roots in 1885, with the invention of the first electric room thermostat. Through our growth strategies and by increasing market share we are committed to delivering value to shareholders and making our customers successful. In 2015, Corporate Responsibility Magazine recognized Johnson Controls as the #14 company in its annual "100 Best Corporate Citizens" list. For additional information, please visit http://www.johnsoncontrols.com or follow us @johnsoncontrols on Twitter.
|
CONTACT: |
Fraser Engerman 414-524-2733 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson-controls-announces-quarterly-dividend-300117157.html
SOURCE Johnson Controls
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
- Organizations help build resilient communities by supporting Red Cross Disaster Relief
- Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share